Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)
- PKA pension fund lead investment, alongside The Danish Growth Fund and Eir Ventures
- New financing will advance clinical trials with Synklino’s drug candidate SYN002 for the treatment of cytomegalovirus (CMV)
Copenhagen, Denmark, 8 June 2022 – Synklino, an emerging biotech company developing breakthrough drugs for the treatment of chronic viral infections, has completed a Series A fundraise of EUR 29.8 million (DKK 222 million / USD 31.8 million) accelerating its development plans towards significant clinical milestones.
